Montreal-based, biotech company Warnex Inc. completed, on July 10, 2002, a financing with SGF Soquia Inc. for $12 million. Warnex also completed, on the same day, the last portion of a private placement of $6 million of which $4,515,000 had been completed in two previous transactions on December 12, 2001 and March 12, 2002. Contemporaneously with these transactions, Warnex purchased the 35 per cent interest in the shares of Genevision Inc. held by 9066-2032 Quebec Inc. (the holding company of Christian Archambault), for a total consideration of $7.35 million payable by the issuance of common shares and warrants of Warnex. Genevision is a diversified genomics-based biotechnology company developing quality control systems using DNA markers for the environmental, agri-food and pharmaceutical markets.
Warnex was represented by Carolyne Lassonde and Christian Marcoux and Rosetta De Luca of Brouillette Charpentier Fortin. SGF Soquia was represented by its parent Société générale de financement du Québec’s in-house counsel Lilia Pouliot, and François Amyot, Philippe Leclerc and Philippe Boivin (intellectual property) of McCarthy Tétrault LLP in Quebec.
9066-2032 Quebec and Christian Archambault were represented by Paul Marcotte, Peter Villani (corporate-securities) and Benoit Dupuis (taxation) of Fasken Martineau DuMoulin LLP in Montreal.
Warnex was represented by Carolyne Lassonde and Christian Marcoux and Rosetta De Luca of Brouillette Charpentier Fortin. SGF Soquia was represented by its parent Société générale de financement du Québec’s in-house counsel Lilia Pouliot, and François Amyot, Philippe Leclerc and Philippe Boivin (intellectual property) of McCarthy Tétrault LLP in Quebec.
9066-2032 Quebec and Christian Archambault were represented by Paul Marcotte, Peter Villani (corporate-securities) and Benoit Dupuis (taxation) of Fasken Martineau DuMoulin LLP in Montreal.
